Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04888338 · ClinicalTrials.gov registry record

Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies

A clinical trial of Hematopoietic and Lymphoid Cell Neoplasm, sponsored by M.D. Anderson Cancer Center.

Recruiting
Registry status
100
Enrollment target
1
Study location

NCT04888338 is a study of Hematopoietic and Lymphoid Cell Neoplasm that is actively recruiting participants, run by M.D. Anderson Cancer Center. The registered enrollment target is 100 participants, below the 952-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (89% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04888338, a study of Hematopoietic and Lymphoid Cell Neoplasm, is actively recruiting participants, sponsored by M.D. Anderson Cancer Center.

RECRUITING
Registry status
100 participants
Enrollment target
1
Study location

Study Summary

This study collects information on outcomes after chimeric antigen receptor therapy and radiation therapy for hematologic malignancies. Collecting information from patients before, during, and after receiving chimeric antigen receptor therapy or radiation therapy may help doctors to optimize patient selection, dose, timing, and sequencing of these treatments.

Interventions

  • OTHER Electronic Medical Record
  • OTHER Data Capture

Study Locations (1)

Texas

  • M D Anderson Cancer Center - Houston

Trial Details

FieldValue
Enrollment Target 100 participants
Start Date 2021-04-10
Est. Completion 2026-11-14

Sponsor

M.D. Anderson Cancer Center

2,692 total trials

What the Registry Record Tells You About NCT04888338

The ClinicalTrials.gov registry entry for NCT04888338 describes a study currently listed as recruiting, categorized as an unspecified phase. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 952-participant average among 104 other Hematopoietic and Lymphoid Cell Neoplasm trials with a reported enrollment target (89% lower). The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Hematopoietic and Lymphoid Cell Neoplasm appearing as the primary indexed condition, and to 2 interventions - of which Electronic Medical Record is the first listed.

NCT04888338 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.

Frequently Asked Questions

What is clinical trial NCT04888338 about?

NCT04888338 is a clinical study titled "Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies". This study collects information on outcomes after chimeric antigen receptor therapy and radiation therapy for hematologic malignancies. Collecting information from patients before, during, and after receiving chimeric antigen receptor therapy or radiation therapy may help doctors to optimize patient...

What is the current status of trial NCT04888338?

This trial is currently recruiting. The enrollment target is 100 participants. The study started on 2021-04-10. Estimated completion is 2026-11-14.

What conditions does trial NCT04888338 study?

This clinical trial studies the following conditions: Hematopoietic and Lymphoid Cell Neoplasm.

What interventions are being tested in trial NCT04888338?

The interventions under investigation include: Electronic Medical Record (OTHER), Data Capture (OTHER).

Who is sponsoring clinical trial NCT04888338?

This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04888338 being conducted?

This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Hematopoietic and Lymphoid Cell Neoplasm

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.